Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

iCAD, Inc announced hosting of second quarter and six months 2009 financial results conference call on Thursday, July 30, 2009

iCAD, Inc (NASDAQ: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, announced that the Company will release financial results for the second quarter and six months ended June 30, 2009, following the close of the market on Wednesday, July 29, 2009.

Ken Ferry, President and Chief Executive Officer, and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer, will host a conference call for investors beginning at 10:00 a.m. Eastern Time on Thursday, July 30, 2009 to discuss second quarter and six months 2009 financial results and to answer questions.

Shareholders and other interested parties may participate in the conference call by dialing 866-783-2140 (domestic) or 857-350-1599 (international) and entering passcode 34348388 a few minutes before 10:00 a.m. ET on Thursday, July 30, 2009. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com and www.icadmed.com.

A replay of the conference call will be accessible two hours after its completion through August 6, 2009 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 93391916. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com and www.icadmed.com.

About iCAD, Inc
iCAD, Inc is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, over 3,100 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, prostate and in the future, colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.

Source: iCAD, Inc